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Concl, :~0n, (1) Imago quality and seventy of mduceq ayssynergy have 
the most stgn¢li~tnt impact on IDA 12) Standard=zation of ,mage d~splay and 
RC results m ~mprovnd IDA on DSE mtorprotatmn 
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Dot~damthe stress echacard~ography (I~$E) commonly uses 3 minute (ram) 
st~ges d~.~pq0 requiting up tO 10 min tO reach steady state. Pnm studies 
have demoestrated the utility 01 prolonged stage duration, but DSE =e already 
a time C0n~ummg test We developed a novel accelerated DSE (AIDSE) 
protocol =n which a single, h~gh dose (40 mcg/kg/mm) infus!on 0t dobutamme 
is admin~teH~:l for UP to 10 minuteS, or unt!l target HR (65% pred~Cled max) 
~s reached. !l !argo! HR was not reached, atropine (0.2 mcojm~n, 1 0 mg 
max) was ~ .  Feas=b~l~y, safety, and eff~cao/of ADSE were assessed 
m patients (pls) with a h~oh pretest hkelihood of CAD. HR, BP, ECG and 
symptoms were assessed at I mm mtervats throughout he intus~on ADSE 
was admmrstered to 47 c o n ~  pfs (46 males, t female) w~th a mean 
age 0t 64 ~ It  years. Patients ~ad an average el 4 4 ~ 1 3 cardiac rink 
factors and 49% had known CAD 
Resorts. ADSE increased the HR (68 ; 2 7to 133 ± 39bpm p -: 0Ot) 
wrth an ~0rage test duration o! 11 4 .. 3 1 mm Target HR was reached =n 
19 of 22 (86%) pts not on beta-bk~:kers (BB) but m only 11 of 25 (44%) pts 
on BB (p = 0 0Of) Symptoms ~nclu<~cl pelp~tat~oes (21%), d~zzmess (12%), 
chest pain (6%), headaches (6%), or nausea (6¢0) There were no eprsodes 
01 sustained VT, VF or senous ad~'erse events. 
Conct~ons. ADSE w~th a continuous h~gh dose ts teas=hie and sate =n 
pts with known or suspected CAD and acl~oves target HR w~h a shorter 
duration Further mvost~jatton with an angmgrsph~c gold standard will be 
necessary to determine the sens~t~ty et ADSE 
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T~d~onal endpo(nts (ENDPT) for terminating dobutam~ne atropine stress 
echocard~o~2aphy (DASE) have been the use el a predetineQ m~x~ma| dose 
el dabutan~ne (DeBt and atropine tAT) or attamrnent of 85% ot maximum age 
prodded heart rate (MPHR), a value denved from exerc=se stress testing 
Whether these constitute opbmum ENDPT for DASE =s unclear 
100 coftsecuttve pos~twe DASE studces performed w~ usual ENDPT 
(85% MPHR 40 to 50 mcejkg/m~n DOB + maximum 2 mg AT, e~enswe wail 
motion ab~ormahty, hyporens~on, or arrhythm~a) were evaluated to assess 
HR. %MPHR. wall mobon Score =ndex, DOB and AT doses when pos=t~wty ot
the study (~orsening ot wall mobon by _: 1 grade) first developed and at peak 
dose. Hypothetical ENDP] tot peak HR and %MPHR were then apphed to 
these 100 DASE to determine optimum DASE pos=ttvtty for ~schemca. At f!rst 
pOSdiVity, ~ose of DOB was 28.8 ~ 10.9 mcg/kg~min (range 5 to 50) and AT 
0.20 : 0.47 mg (range 0 to 2) vs DOB 365 -. 81 mcg.~.g/mln and AT 0.5 : 
0.7 mg at study complebon 
HR (bprn t %DASE * %MPHR %DASE * 
110 73% 70 70% 
115 63% 75 90% t 
120 96%" 80 95% t 
130 99%" 85 g~% 
"D OO01v~ 110~nd115bDm t p - OO01vsT0%MPHR 
There was no s~gnihcant difference ~n DASE POs~twity ublizlng ENDPT 
o1 HR 120 bpm vs. 75% MPHR At traditional ENDPT of 85% MPHR or 
maximum DOB and AT dose. diagnosis was changed from stogie vessel 
CAD to multivessel disease in only 6 studies 
In conclusion, optimum ENDPT for DASE include HR 120 bpm or 75% 
MPHR in addition to ischemia, hypotens=on, or arrhythm~a. 
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A significant percent of pts undergoing dobutamine stress echocardiography 
(DSE) will fail to roach target heart rate with dobutamine alone and will require 
atropine (ATR). We have previously defined c~ter~3 whici~ predict failure to 
reach "-85% PMA× by 12 rain (end ot Stage 4 - 40 mcg/kg/min) of standard 
DS~ protocol Those cnterla are Age , 50 yrs OR HR at basehne , 60 b(.'.'.'.'.'.'.'.'.~ 
OR HR ~t end el 6 mTn (Stage 2 • 20 mcg/kgJmen) , 60% PMAX $4 pls 
meehng these cntena were rsn00mly as$1grted to o1111et a St~lnCL~fO McNe~t 
protOCOl (,n which 0 25 mg ATR 0S given (I I mm after ¢ompletK)f~ ot Stage 4 
to a 101~! 0OSe of I me) (Group IA, n =~ 25) or early atropine prolocol (Gr~ 
1B, n ~ ;~9) in whch 0.25 mg ATR was given at the I~nnmg o! Stage 3 ar~l 
el $tag~ 4 with an add tonal 0~'5 mg ATR given at 13 and 14 mm ~f ne~ 
These p~t=ents were compared addit~ona!ly wrth 30 ~ who were pre~ct~ 
to achieve ~65% PMAX and reca ve¢! a slan(t~rO McNeflt protocol (Grout) 
2) Time to peak HR wa~ shorter ~n Group !1~ man m Group 1A (120 ~ 0 3 
vs !37 ~. 03 m,n, p = 0001), although sldt longer than ~n Group 2 (104 
05 ram, p = 0.01) In add,t~on, Group IB and Group 2 had sire, let rates ot 
dachne in HR aft0r stgdy ten~matton, reaching 6~ ~ I% and 88 ~- ~,= PMAX 
respec1=vely at 6 m=n po~t, HR in Group 1A remained h~gher, longer, tatting 
to only 72 ~ ~% at 6 mm POSt (p = 0 01 ) Graph t)elow shows stage at wh,ch 
pls reached peak HR 
co% 
"~ Group 1A 
Group tB i 
4o% JGroup 2 II 
S~ge t §t~m2 ~;Ige ~ Srige 4 t3ntn 14nml timm le~ ,~n 
Conclusions: I) Early atropine use sigmfcantly shortens DSE pmtocal 2) 
HR returns to baseline values quicker wrth early atmpme administration 
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Kinetic exerose increases the cardiac output and pulmonary blood flow 
and consequently pulmonary artery syslohc pressure (PASP) However the 
upper physiologic Iirmt el PASP response to exercise has not been completely 
addressed The obiect=ve ot th~s tudy was to dehne the spectrum of PASP 
dunng exercTse 
Methods: From 1994 to 1997. 102 suiolecls (mean age 369 : t 5 6, range 
21 to 80 years) 156 men, 46 womer~) underwen! a standardized sam=recum- 
bent echo Doppler t~cycle exercise PASP was calculated by me formula 4 
• tncusp~d regurgAatlon velocd~ + 14 mmHg (nght atnal pressure) There 
were 40 normal controls (I). and 62 patients (11) with known or suspected 
pulmonary hypertension referred to our lnstltutmn for testing 
Resutrs: The 95% confidence intervals (CI) for mean PASP were calcu- 
lated tot normal cc'~trols (table below). The upper limit (mmHg) tot normels 
was: 
Wails Re~t 40 80 120 160 200 24(} 
UI3per CI I~n1~1 35 8 42 1 45 8 48 9 60 8 59 3 67 3 
e l  the petlents Kn group II 49 had PASP at rest and at each stage .g5% CI 
seen =n normats, 8 had exero~e reduced PASP (ExPASP) and S had normal 
PASP at rest and dunng exerc~¢': 
Conc/u:~ton (at Phys=olog~c range ot PASP dunng stress ts h~gher than 
previously recognized and provides a standard for the dlagnes=s el pulmonary 
hypertens=on: (b) The prP.senco el ExPASP confirms that resting normal 
PASP does not exclude occult abnormaht~es of the pulmonar~ vessels 
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• Effect of Interpretation of Digital Rhythm on 
Echocard icgrams 
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Back¢; =Jnd: We have shown that digital echo tDE) =s a reliable substitute 
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